EN DE
Watch Inhalation Sciences Sweden AB for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Inhalation Sciences Sweden AB (ISAB) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of Inhalation Sciences Sweden AB stock SEK 0.09, price SEK 0.06, upside +54.0%, quality 36 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE

IS Inhalation Sciences Sweden AB logo Thin data Nov 14, 2026

Inhalation Sciences Sweden AB

ISAB · ST

Cheap (35% below fair value), but weak company and falling price: meets 1 of 3 rules.

Follow free in the weekly email
Fair value kr 0.0853 · Strongly undervalued 
Low debt 
Even on cautious assumptions the value is 9% above the price (kr 0.0604). 
Mixed vs. peers (5/10) 
Changed on Oct 25: SEK 0.1029 → SEK 0.0814 
Quality 36/100 
Falling price (downtrend) 
Weak Growth (revenue 3y −37.1 %/yr in SEK) 
Loss-making · -103.1% net margin (TTM) 
Negative free cash flow 
Narrow moat 4/100 · thin data
Thin data 
⚠ Dilution⚠ Thinly traded
Watch Inhalation Sciences Sweden AB for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 11.20 kr 0.0484 Fair Value kr 0.0853 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range kr 0.0484 – kr 11.20 · fair‑value band kr 0.0604 – kr 0.1002 · the kr 0.0554 price screens below the kr 0.0853 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Inhalation Sciences Sweden in your weekly email

Every Wednesday you see whether Inhalation Sciences Sweden is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research in Sweden.

Show moreShow less

The company offers PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exposure used in preclinical testing of inhalation drugs, as well as for inhalation toxicity studies in rodents; and intratracheal exposure module, an unique technology delivering aerosol directly to the lungs, bypassing the nose, and to spontaneously breathing rodents.

Inhalation Sciences Sweden AB (publ) was incorporated in 2004 and is based in Huddinge, Sweden.

Stock analysis

Inhalation Sciences Sweden AB (ISAB) currently trades at kr 0.0554, while our model-based Fair Value estimate is kr 0.0853, implying the stock looks roughly 35% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: kr 0.0604 (bear) to kr 0.1002 (bull), the price of kr 0.0554 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Inhalation Sciences Sweden AB reported revenue of 3.0M SEK in FY2025 versus 12.2M SEK in FY2022, a compound −37.1%/yr. Reported net income was −10.2M SEK in FY2025.

Key figures

Market cap 4.1M SEK (≈ $408K) Micro · P/S ratio 0.50 · EPS (TTM) kr −0.2100 · Net margin −103% · Return on equity −90.0% · Return on assets (EBIT) −67.0% (4-year average) · Operating margin −65.0% · Revenue (TTM) 8.3M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 4 out of 100 (low confidence).

What moves the price

The share trades about 89% below its 52-week high and 14% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 54%, ISAB screens cheaper than that median.

Fair Value models

Bear kr 0.0604 Fair Value kr 0.0853 Bull kr 0.1002
Price kr 0.0554 · Upside +54.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 0.0800 kr 0.1300 kr 0.1600 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.0800 kr 0.1300 kr 0.1600 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 34
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−72.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−98.6% (2022) → −333.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ISAB, get fair value alerts →

Compare Inhalation Sciences Sweden AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside +54.0% · Top 25%
Profitability
Return on assets −106.6% · Bottom 25%
Net margin (12 months) −103.1% · Bottom 25%
Operating margin (12 months) −65.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 246.8% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.57× · Cheapest 25%
P/S (12 months) 0.50× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 19
FUTURE (revenue growth)100 · sector 43
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Boston Scientific Corporation BSX $43.64 $48.00 +10% vs ISAB
DexCom, Inc DXCM $82.52 $90.77 +10% vs ISAB
STERIS plc STE $259.57 $283.15 +9% vs ISAB
Stryker Corporation SYK $318.15 $340.60 +7% vs ISAB
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.80 ¥197.34 +7% vs ISAB
GE HealthCare Technologies Inc GEHC $83.66 $69.92 −16% vs ISAB
Edwards Lifesciences Corporation EW $105.23 $81.94 −22% vs ISAB
Medtronic plc MDT $100.72 $74.89 −26% vs ISAB
Abbott Laboratories, ABT $104.48 $75.28 −28% vs ISAB
Koninklijke Philips N.V PHIA €26.77 €15.23 −43% vs ISAB

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Inhalation Sciences Sweden AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Inhalation Sciences Sweden AB Fair Value". https://www.fairvalue-calculator.com/stock/ISAB

Frequently asked questions

Is Inhalation Sciences Sweden AB (ISAB) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of kr 0.0853 versus a price of kr 0.0554, about +54% upside (undervalued).
What is the fair value of ISAB?
Our model-based fair value for Inhalation Sciences Sweden AB is kr 0.0853 (as of Nov 14, 2026), built from audited fundamentals. The current price: kr 0.0554.
What is the quality score of ISAB?
Inhalation Sciences Sweden AB has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Inhalation Sciences Sweden AB (ISAB)?
We do not set a price target; the yardstick is the fair value of kr 0.0853 (as of Nov 14, 2026) from 1 valuation models. Cautious scenario kr 0.0604, optimistic scenario kr 0.1002. It is a calculation from audited fundamentals, not an analyst target.
What is the Inhalation Sciences Sweden AB stock forecast for 2026?
Our models put fair value at kr 0.0853, about +54% upside versus a price of kr 0.0554 (undervalued). Cautious scenario kr 0.0604, optimistic scenario kr 0.1002. The calculation is refreshed regularly with new filings.
What is the revenue of Inhalation Sciences Sweden AB (ISAB)?
Inhalation Sciences Sweden AB reported trailing-twelve-month revenue of about 8.3M SEK (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of Inhalation Sciences Sweden AB (ISAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Inhalation Sciences Sweden AB it is kr 0.0853 per share (as of Nov 14, 2026), against a price of kr 0.0554. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Inhalation Sciences Sweden AB stock overvalued or undervalued in 2026?
As of Nov 14, 2026, ISAB trades below its calculated fair value: price kr 0.0554, fair value kr 0.0853, a gap of about +54% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ISAB?
No. The price is what the market pays today (kr 0.0554); the fair value is what the company's own numbers justify (kr 0.0853). For Inhalation Sciences Sweden AB the two are kr 0.0299 per share apart. That gap is exactly why we show both numbers side by side.
How much is Inhalation Sciences Sweden AB worth?
The market values Inhalation Sciences Sweden AB at about 4.1M SEK (market capitalisation, as of Nov 14, 2026). Per share that is kr 0.0554; our models calculate a fair value of kr 0.0853 per share.
What do the bullish and bearish scenarios say about ISAB?
Our models span a range for Inhalation Sciences Sweden AB: cautious scenario kr 0.0604, base kr 0.0853, optimistic kr 0.1002 per share (as of Nov 14, 2026, price kr 0.0554). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Inhalation Sciences Sweden AB (ISAB)?
Balance-sheet figures for Inhalation Sciences Sweden AB (as of Nov 14, 2026): return on equity −90.0%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is ISAB from its 52-week high?
Inhalation Sciences Sweden AB trades at kr 0.0554, about 89% below its 52-week high of kr 0.5000 and 14% above the low of kr 0.0484 (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0853 is for.
Which stocks are comparable to Inhalation Sciences Sweden AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Inhalation Sciences Sweden AB stock attractive at the current price?
The data as of Nov 14, 2026: price kr 0.0554, calculated fair value kr 0.0853 (+54%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ISAB calculated?
We run Inhalation Sciences Sweden AB through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of kr 0.0853 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Inhalation Sciences Sweden AB currently trades 35% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Inhalation Sciences Sweden AB (ISAB)?
The closing price on Nov 18, 2026 was kr 0.0554. Our model-based fair value is kr 0.0853, about +54% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Inhalation Sciences Sweden AB right now?
The large discount to fair value meets weak quality (36/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (kr 0.0604). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Inhalation Sciences Sweden AB

How large is the market capitalisation of Inhalation Sciences Sweden AB (ISAB)?
The market capitalisation of Inhalation Sciences Sweden AB is 4.1M SEK (≈ $408K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Inhalation Sciences Sweden AB (ISAB)?
The price-to-sales ratio of Inhalation Sciences Sweden AB is 0.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Inhalation Sciences Sweden AB (ISAB)?
Earnings per share at Inhalation Sciences Sweden AB are kr −0.2100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Inhalation Sciences Sweden AB (ISAB)?
The net margin of Inhalation Sciences Sweden AB is −103% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Inhalation Sciences Sweden AB (ISAB)?
The return on equity (ROE) of Inhalation Sciences Sweden AB is −90.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Inhalation Sciences Sweden AB (ISAB)?
On an EBIT basis the return on assets of Inhalation Sciences Sweden AB is −67.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Inhalation Sciences Sweden AB (ISAB)?
The operating margin of Inhalation Sciences Sweden AB is −65.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Inhalation Sciences Sweden AB (ISAB)?
Revenue at Inhalation Sciences Sweden AB is growing 247% versus a year earlier (3y avg −37.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Inhalation Sciences Sweden AB (ISAB) generate?
The free cash flow of Inhalation Sciences Sweden AB is −10.8M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Inhalation Sciences Sweden AB in the live analysis

One click puts Inhalation Sciences Sweden AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.